Thus, the PPARα-activating nucleoside analogs tenofovir-disoproxil-fumarate may usefully treat atherosclerosis and hepatocarcinogenesis, both of which are associated with dyslipidemia. This evidence concerns the gene PPARA and metabolic syndrome.